TytoCare

Company Overview

Snapshot

Founded in June 2012 by Dedi Gilad and Ofer Tzadik, TytoCare operates with 201–500 employees. The company has raised over $228.6 million across 9 funding rounds from 20 investors, with Insight Partners leading a recent round. In July 2026, TytoCare named Adam Pellegrini as CEO and closed a growth round to scale its AI-first clinical enablement platform.

Business overview

TytoCare is a virtual healthcare company that provides remote healthcare solutions through its Home Smart Clinic. This offering combines an FDA-cleared device with AI-powered guidance and diagnostic support, enabling families to conduct remote physical exams with a doctor. The company also offers the Pro Smart Clinic for professional settings. TytoCare serves over 220 major health systems and health plans globally, operating within the Health Tech & Life Sciences sector, focusing on digital healthcare, medical devices, and diagnostics.

Strategic signal

In July 2025, TytoCare underwent a significant restructuring, including workforce optimization and a leadership change with co-founder Dedi Gilad stepping down from day-to-day management to focus on long-term strategy. This strategic pivot signals a renewed focus on the US market and the development of AI-based diagnostic capabilities, indicating a shift towards addressing the growing shortage of family physicians and enhancing its core technology offerings.

Company Intelligence Q&A

What was a significant recent development for TytoCare's leadership and funding?

In July 2026, TytoCare named Adam Pellegrini as its new CEO and closed a growth funding round of $25 million to scale its AI-first clinical enablement platform. This round was led by Insight Partners.

What strategic changes did TytoCare implement in July 2025?

In July 2025, TytoCare underwent a restructuring that included workforce optimization and a shift in focus towards the US market and the development of FDA-approved AI diagnostics. Co-founder Dedi Gilad transitioned from daily management to long-term strategy.

What new AI-powered diagnostic capability did TytoCare receive FDA clearance for in July 2024?

In July 2024, TytoCare received FDA clearance for its AI Lung Crackle Detection, enhancing its diagnostic capabilities for remote physical examinations.

What recognition did TytoCare's AI Respiratory Suite receive in October 2025?

In October 2025, TytoCare's AI Respiratory Suite was recognized by TIME magazine, being listed among its Best Inventions of 2025.

What was the outcome of TytoCare's Series D funding extension in March 2021?

In March 2021, TytoCare raised an additional $50 million in an extended Series D funding round. This round saw participation from investors including Insight Partners and West Fountain Global Fund.